Cargando…
Pharmacokinetic of Cefiderocol in Critically Ill Patients Receiving Renal Replacement Therapy: A Case Series
Background: Cefiderocol is a novel parenteral siderophore cephalosporin, demonstrating enhanced activity against multidrug-resistant (MDR) Gram-negative bacteria and difficult-to-treat Acinetobacter baumannii (DTR-AB). Plasma-free trough concentration (fC(trough)) over the minimum inhibitory concent...
Autores principales: | Mornese Pinna, Simone, Corcione, Silvia, De Nicolò, Amedeo, Montrucchio, Giorgia, Scabini, Silvia, Vita, Davide, De Benedetto, Ilaria, Lupia, Tommaso, Mula, Jacopo, Di Perri, Giovanni, D’Avolio, Antonio, De Rosa, Francesco Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774561/ https://www.ncbi.nlm.nih.gov/pubmed/36551485 http://dx.doi.org/10.3390/antibiotics11121830 |
Ejemplares similares
-
Meropenem/Vaborbactam and Cefiderocol as Combination or Monotherapy to Treat Multi-Drug Resistant Gram-Negative Infections: A Regional Cross-Sectional Survey from Piedmont Infectious Disease Unit Network (PIDUN)
por: Lupia, Tommaso, et al.
Publicado: (2022) -
2019 novel coronavirus (2019-nCoV) outbreak: A new challenge
por: Lupia, Tommaso, et al.
Publicado: (2020) -
Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections
por: Stroffolini, Giacomo, et al.
Publicado: (2022) -
COVID-19 pneumonia: do not leave the corticosteroids behind!
por: Pinna, Simone Mornese, et al.
Publicado: (2021) -
Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?
por: Mornese Pinna, Simone, et al.
Publicado: (2021)